SCHEMBL1493522

SCHEMBL1493522

COc1ccc(-n2nccc2NC(=O)CSc2nnnn2-c2c(C)cccc2C)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
ALDH1A1 P00352 5/20 0.58
NTRK1 P04629 1/20 0.57
NTRK2 Q16620 1/20 0.57
HTT P42858 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.54
TSHR P16473 1/20 0.54
MAPT P10636 3/20 0.54
USP2 O75604 1/20 0.54
HPGD P15428 1/20 0.54
HK1 P19367 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
LMNA P02545 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1493562 0.92 CYP1A2 (0.58) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1493610 0.90 CYP1A2 (0.61) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1493372 0.87 ALDH1A1 (0.55) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1612428 0.85 ALDH1A1 (0.60) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1493438 0.84 ALDH1A1 (0.61) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1493454 0.83 ALDH1A1 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1610263 0.83 HSD11B1 (0.42) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1611457 0.83 ALDH1A1 (0.60) ALDH1A1NTRK1NTRK2HTTSMN1; SMN2
SCHEMBL1493410 0.82 CYP3A4 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL1612937 0.82 ALDH1A1 (0.51) CYP1A2CYP3A4CYP2D6CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-04-14 US claimed
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-04-14 US disclosed
EP-2288603-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2011-03-02 EP disclosed
WO-2009150614-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R CYP1A2 1066/4885CYP3A4 1167/4885CYP2D6 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.